Whither accelerated approval?
Amid the hubbub over new Medicare coverage restrictions for Alzheimer’s treatments, a key issue may not be fully appreciated: There is now bona fide pushback against accelerated approval, a controversial strategy used by regulators and companies to get new drugs to market faster than usual.
On its face, this suggests potentially wider — and sobering — implications for the pharmaceutical industry and patients, because they may one day have to wait longer for new medicines to get out the proverbial door.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect